Hematology, Transfusion and Cell Therapy (Oct 2023)

DEVELOPMENT OF GIANT PLASMACYTOMA IN A PATIENT WITH BONE MARROW RESPONSE DURING TREATMENT: A CASE REPORT

  • Rafiye Ciftciler,
  • Serhat Sayın,
  • Mehmet Daglı

Journal volume & issue
Vol. 45
p. S38

Abstract

Read online

Objective: A plasmacytoma is a myelomatous mass that can develop into a widespread illness, be seen alone, or be combined with multiple myeloma (MM). Bone marrow does not always indicate MM, but over the course of 4-5 years, about 50% of cases advance to this disease. In this study, we aimed to present a patient who was diagnosed with multiple myeloma and developed giant plasmacytoma despite bone marrow response during follow-up. Case report: During the 4th cycle, a giant plasmacytoma developed at the patient's right arm proximal humerus level.Ultrasound imaging performed on the right upper extremity was reported as 'Diffuse skin-subcutaneous thickness, increased echogenicity and linear fluid areas were observed. A large 5 × 3 cm hypoechoic nodular lesion with markedly increased blood flow was observed in the proximal medial neighborhood of the patient's incision line. Plasmacytoma continued to shrink with radiotherapy and chemotherapy Methodology: At the time of diagnosis, EPs are seen in around 7% of individuals with MM and are best identified by PET/CT scans; the presence of EP is linked to a worse prognosis. Later in the course of the disease, 6% more patients will get EP. Large, crimson-colored, subcutaneous masses can be a symptom of EP. The creases on the palms and/or soles may be affected by plane xanthomas, which may be a paraneoplastic condition. Rarely, cutaneous spicules made partially of the monoclonal (M) protein may form.Results Conclusion: We presented a case that developed a giant plasmacytoma based on multiple myeloma. This case is important because, after the diagnosis, a giant plasmacytoma developed during the 4th cycle of chemotherapy, although the patient's laboratory examinations and clinic responded to chemotherapy after 3 cycles of chemotherapy.